Heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) emerged before the clinical introduction of vancomycin in Japan: A retrospective study

Journal of Infection and Chemotherapy

Volumn 18, Issue 3, 2012, Pages 406-409

  Yamakawa, Jun ^a   Aminaka, Mayumi ^a   Okuzumi, Katsuko ^b   Kobayashi, Hiroyoshi ^c   Katayama, Yuki ^a   Kondo, Shigemi ^a   Nakamura, Ayako ^a   Oguri, Toyoko ^a,d   Hori, Satoshi ^a   Cui, Longzhu ^a   Ito, Teruyo ^a   Jin, Jingxun ^a   Kurosawa, Hisashi ^a   Kaneko, Kazuo ^a   Hiramatsu, Keiichi ^a  

^a JUNTENDO UNIVERSITY   (Japan)

^b DOKKYO MEDICAL UNIVERSITY   (Japan)

^c TOKYO HEALTHCARE UNIVERSITY   (Japan)

^d KAMEDA MEDICAL CENTER   (Japan)

Author keywords

HVISA; Imipenem; Vancomycin; VISA

Indexed keywords

BETA LACTAM ANTIBIOTIC; FLOMOXEF; GENTAMICIN; IMIPENEM; MINOCYCLINE; OFLOXACIN; OXACILLIN; RIFAMPICIN; VANCOMYCIN;

ARTICLE; BACTERIAL STRAIN; CLPP GENE; GENE; GENE MUTATION; HETEROGENEOUSLY VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; HUMAN; JAPAN; JAPANESE; MAJOR CLINICAL STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NUCLEOTIDE SEQUENCE; PREVALENCE; PULSED FIELD GEL ELECTROPHORESIS; RETROSPECTIVE STUDY; RPOB GENE; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT FAILURE; VANCOMYCIN INTERMEDIATE STAPHYLOCOCCUS AUREUS; VRASR GENE; WALRK GENE;

EID: 84863309419     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1007/s10156-011-0330-2     Document Type: Article

References (13)

1. Hiramatsu K, Okuma K, Ma XX, Yamamoto M, Hori S, Kapi M. New trends in Staphylococcus aureus infections: glycopeptide resistance in hospital and methicillin resistance in the community. Curr Opin Infect Dis. 2002;15:407-13.
2. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997;350:1670-3.
3. Howden BP, Davies JK, Johnson PD, Stinear TP, Grayson ML. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin- intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23: 99-139.
4. Katayama Y, Murakami-Kuroda H, Cui L, Hiramatsu K. Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem. Antimicrob Agents Chemother. 2009;53: 3190-6.
5. Tanaka T, Okuzumi K, Iwamoto A, Hiramatsu K. A retrospective study of methicillin-resistant Staphylococcus aureus clinical strains in Tokyo University Hospital. J Infect Chemother. 1995;1: 40-9.
6. Hiramatsu K. Molecular evolution of MRSA. Microbiol Immunol. 1995;39:531-43.
7. Watanabe S, Ito T, Sasaki T, Li S, Uchiyama I, Kishii K, et al. Genetic diversity of staphylocoagulase genes (coa): insight into the evolution of variable chromosomal virulence factors in Staphylococcus aureus. PLoS One. 2009;4:e5714.
8. Chongtrakool P, Ito T, Ma XX, Kondo Y, Trakulsomboon S, Tiensasitorn C, et al. Staphylococcal cassette chromosome mec (SCCmec) typing of methicillin-resistant Staphylococcus aureus strains isolated in 11 Asian countries: a proposal for a new nomenclature for SCCmec elements. Antimicrob Agents Chemother. 2006;50:1001-12.
9. Kato Y, Suzuki T, Ida T, Maebashi K, Sakurai M, Shiotani J, et al. Microbiological and clinical study of methicillin-resistant Staphylococcus aureus (MRSA) carrying VraS mutation: changes in susceptibility to glycopeptides and clinical significance. Int J Antimicrob Agents. 2008;31:64-70.
10. Shoji M, Cui L, Iizuka R, Komoto A, Neoh HM, Watanabe Y, et al. The walK and clpP Mutations Confer Reduced Vancomycin Susceptibility on Staphylococcus aureus. Antimicrob Agents Chemother. 2011;55:3870-81.
11. Cui L, Isii T, Fukuda M, Ochiai T, Neoh HM, Camargo IL, et al. A RpoB mutation confers dual hetero-resistance to daptomycin and vancomycin in Staphylococcus aureus. Antimicrob Agents Chemother. 2010;54:5222-33.
12. Cui L, Neoh HM, Shoji M, Hiramatsu K. Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin- intermediate Staphylococcus aureus. Antimicrob Agents Chemother. 2009;53:1231-4.
13. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis. 2001;1: 147-55.